MECP2 and neurodegenerative disease: Thus, the reduced phosphorylation of S423 in the early stages of AD-related neurofibrillary pathology suggests a potential compensatory effect in AD brain undergoing neurodegeneration, which in turn reinforces the idea that PTMs in MECP2 are potential targets for developing specific therapies against AD and other neurodegenerative diseases.